<DOC>
	<DOCNO>NCT00905190</DOCNO>
	<brief_summary>This study assess effect food single dose EUR-1025 take meal take empty stomach .</brief_summary>
	<brief_title>Bioavailability Study Anti Nausea Medication With Without Food</brief_title>
	<detailed_description>The objective study assess effect food pharmacokinetics single 24 mg dose EUR-1025 administer novel modified-release capsule formulation feed fasting condition .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Male female volunteer , Non exsmokers , Of least 21 year age old 55 year body mass index target least 18.5 less 30 kg/m2 , Healthy , normal lab value , Negative HIV , Hepatitis B &amp; C negative ethyl alcohol drug screen , Normal 12 lead ECG , negative human chorionic gonadotropin ( hCG ) female . No known hypersensitivity Ondansetron related product , Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect , History significant gastrointestinal , liver kidney disease , Presence significant cardiovascular , pulmonary , hematologic , neurological , psychiatric , endocrine , immunologic dermatologic disease , Suicidal tendency , History disposition seizure , state confusion , clinically relevant psychiatric disease , Presence significant heart disease disorder discover screen ECG , Females find positive serum pregnancy test screen nursing , Females childbearing potential refuse use acceptable contraceptive regimen screen visit throughout study , Maintenance therapy drug , Significant history drug dependency alcohol abuse ( &gt; 2 unit alcohol per day , intake excessive alcohol , acute chronic ) , Any clinically significant illness previous 28 day day 1 study , Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin rifampin ) , previous 28 day day 1 study , Volunteers take Investigational Product ( another clinical trial ) donate 50 ml blood previous 28 day day 1 study , Poor motivation , intellectual problem likely limit validity consent participate study limit ability comply protocol requirement inability cooperate adequately , Inability understand observe instruction physician , Donation 500 ml blood ( Canadian Blood Services , HemaQuebec , clinical study ) previous 56 day day 1 study , Positive urine screen drug abuse , Any history tuberculosis and/or prophylaxis tuberculosis , Positive result HIV , HBsAg , antiHCV test , No subject allow enroll study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>